How new antibiotics work in ICU patients on organ support
Part of Infections, Kidney & urinary clinical trials.
This study looks at how well certain new antibiotics work in patients who are very ill in the ICU, especially those who need machines like ECMO or dialysis to help their organs. It checks how the drugs behave in your body so doctors can give the right dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need to be in the intensive care unit (ICU).
- You may or may not be on ECMO (a heart-lung machine) or dialysis (kidney support).
- You must have a bacterial infection that can be treated with certain new antibiotics.
- You cannot have allergies to the study drugs or their ingredients.
- You must have a life expectancy of at least one month, not be pregnant, and have a body mass index (BMI) under 45.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how anti-infection drugs work in critically ill patients who are on ECMO, a machine that helps the heart and lungs. The goal is to find the right doses so the drugs work better and are safer for people in this condition.
This study looks at how certain antibiotics behave in your body when you are on VA-ECMO. The goal is to find the right dose to treat your infection effectively and safely.
This trial studies how to give the right dose of common antibiotics to children on ECMO (a heart-lung bypass machine). The goal is to help doctors choose the best dose to fight infections while keeping the child safe.
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Hear when a new ICU Patients With ECMO And-or RRT and With Gram Negative Infections Susceptible to BL-BLIs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.